SLC5A2 and obesity disorder: In this study, we aimed to assess the risk of SIS in new users of GLP-1RA to treat type 2 diabetes mellitus in individuals with obesity, when compared with new users of sodium-glucose cotransporter 2 inhibitors (SGLT-2i).